Tejpar, Bertagnolli, Bosman et al. 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 cer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17:1349 –1355. André T, Boni C, Navarro M et al. Improved overall survival with oxali- platin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109 –3116. Van Cutsem E, Labianca R, Bodoky G et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with iri- notecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27:3117–3125. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leu- covorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin On- col 2007;25:3456 –3461. Le Voyer TE, Sigurdson ER, Hanlon AL et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21:2912–2919. Bosman FT, Yan P, Tejpar S et al. Tissue biomarker development in a multicentre trial context: A feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial. Clin Cancer Res 2009;15:5528 – 5533. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006;25:7531–7537. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525–532. Vogelstein B, Fearon ER, Kern SE et al. Allelotype of colorectal carcino- mas. Science 1989;244:207–211. Baker SJ, Fearon ER, Nigro JM et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217–221. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009;361:2449 –2460. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643– 649. Lothe RA, Peltomaki P, Meling GI et al. Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history. Cancer Res 1993;53:5849 –5852. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004;23:11–27. Aaltonen LA, Peltomäki P, Leach FS et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812– 816. Ionov Y, Peinado MA, Malkhosyan S et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carci- nogenesis. Nature 1993;363:558 –561. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159 –170. Kane MF, Loda M, Gaida GM et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57: 808 – 811. Cunningham JM, Christensen ER, Tester DJ et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Can- cer Res 1998;58:3455–3460. Hendriks YM, de Jong AE, Morreau H et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal car- cinoma): A guide for clinicians. CA Cancer J Clin 2006;56:213–225. 25 Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch www.TheOncologist.com 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 401 repair-deficient human cancers: Toward a new concept of target genes for instability. Cancer Res 2002;62:2447–2454. Miquel C, Jacob S, Grandjouan S et al. Frequent alteration of DNA dam- age signalling and repair pathways in human colorectal cancers with mi- crosatellite instability. Oncogene 2007;26:5919 –5926. Oliveira C, Pinto M, Duval A et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003; 22:9192–9196. Toyota M, Ahuja N, Ohe-Toyota M et al. CpG island methylator pheno- type in colorectal cancer. Proc Natl Acad Sci U S A 1999;96:8681– 8686. Shen L, Toyota M, Kondo Y et al. Integrated genetic and epigenetic anal- ysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 2007;104:18654 –18659. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and micro- satellite instability. J Natl Cancer Inst 2004;96:261–268. Koopman M, Kortman GA, Mekenkamp L et al. Deficient mismatch re- pair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266 –273. Gryfe R, Kim H, Hsieh ET et al. Tumor microsatellite instability and clin- ical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342:69 –77. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemo- therapy for colon cancer. N Engl J Med 2003;349:247–257. Halling KC, French AJ, McDonnell SK et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999;91:1295–1303. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite in- stability and colorectal cancer prognosis. J Clin Oncol 2005;23:609 – 618. Roth AD, Tejpar S, Yan P et al. Stage-specific prognostic value of molec- ular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60 – 00 trial [abstract 4002]. J Clin On- col 2009;27(15 suppl):169s. Kerr D, Gray R, Quirke P et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study [abstract 4000]. J Clin Oncol 2009;25(15 suppl):169s. Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001;1:104 – 109. Sargent DJ, Marsoni S, Thibodeau SN et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials [abstract 4008]. J Clin Oncol 2008;26:180s. Jover R, Zapater P, Castells A et al. The efficacy of adjuvant chemother- apy with 5-fluorouracil in colorectal cancer depends on the mismatch re- pair status. Eur J Cancer 2009;45:365–373. Bertagnolli MM, Niedzwiecki D, Compton CC et al. Microsatellite insta- bility predicts improved response to adjuvant therapy with irinotecan, flu- orouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009;27:1814 –1821. Tejpar S, Bosman F, Delorenzi M et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irino-